EBS · Emergent BioSolutions Inc.
$7.63
-0.06 (-0.78%)
At close · Jul 17
Market Cap
$393.68M
Shares
51,596,296
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$742.9M
-28.8%
FY2025
Net Income
$52.6M
+127.6%
FY2025
Gross Margin
30.27%
-4pp
FY2023
Operating Margin
13.47%
+23.9pp
FY2025
Diluted EPS
$0.93
+125.8%
FY2025
Operating Cash Flow
$170.6M
+190.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $676.8M | $742.9M | $1.04B | $1.05B | $1.12B | $1.79B | $1.56B | $1.11B | $782.4M | $560.87M | $488.78M | $522.79M | $450.14M | $312.75M | $281.89M | $273.38M | |
| — | — | — | — | — | $62.1M | $30.5M | — | — | — | — | — | — | — | — | — | |
| $309.7M | $326.2M | — | $705.4M | $693.1M | — | $524M | $433.5M | $322.3M | $195.71M | $131.28M | $124.3M | $118.41M | $62.13M | $46.08M | $42.17M | |
| $345.8M | — | — | $317.6M | $383M | — | — | $77.8M | $11.2M | $53.08M | $50.93M | — | — | — | — | — | |
| — | — | — | 30.27% | 34.27% | — | — | 7.03% | 1.43% | 9.46% | 10.42% | — | — | — | — | — | |
| $48.6M | $53.2M | $70.7M | $111.4M | $188.3M | $234M | $234.5M | $226.2M | $142.8M | $97.38M | $108.29M | $154M | $150.83M | $119.93M | $120.23M | $124.83M | |
| $180.3M | $186.1M | $308M | $368.4M | $339.5M | $348.4M | $303.3M | $273.5M | $202.5M | $143.5M | $143.69M | $148.46M | $122.84M | $87.88M | $76.02M | $74.28M | |
| $65.3M | $65.1M | $65.1M | $65.6M | $59.9M | $58.5M | $59.8M | $58.7M | $25M | $8.57M | $6.89M | $9.27M | -$8M | — | — | — | |
| — | $95.8M | $108.8M | $125.1M | — | — | $50.1M | $49.5M | $36.32M | $32.24M | $28.02M | $24.5M | $23.01M | $18.96M | $11.2M | $9.36M | |
| — | -$2.1M | $22.5M | $29.3M | — | — | — | — | — | — | — | — | $0 | $2.68M | $3.1M | — | |
| — | — | — | — | — | — | — | $991.9M | $692.6M | — | — | — | — | — | — | — | |
| $60.7M | $100.1M | -$108.7M | -$726.4M | -$170M | $352.6M | $433.8M | $114.1M | $89.8M | $124.29M | $105.52M | $96.04M | $58.06M | $42.8M | $29.97M | $32.1M | |
| — | 13.47% | -10.42% | -69.23% | -15.21% | 19.67% | 27.89% | 10.32% | 11.48% | 22.16% | 21.59% | 18.37% | 12.9% | 13.69% | 10.63% | 11.74% | |
| — | $195.9M | $100K | -$601.3M | — | — | $483.9M | $163.6M | $126.12M | $156.53M | $133.55M | $120.54M | $81.06M | $61.76M | $41.16M | $41.45M | |
| $55.6M | $59.3M | $71M | $87.9M | $37.3M | $34.5M | $31.3M | $38.4M | $9.9M | $6.59M | $7.62M | $6.52M | $8.24M | $0 | $6000 | $0 | |
| $1.39M | — | — | — | — | — | — | — | — | $1.75M | $1.05M | $572K | $320K | $139K | $134K | $105K | |
| -$57.2M | -$17.3M | -$34.2M | -$4.8M | -$49M | -$38.2M | -$26.6M | -$36.7M | -$8.3M | -$5.65M | -$6.3M | -$6.27M | -$4.99M | $565K | $2.1M | -$156K | |
| $3.5M | $82.8M | -$142.9M | -$731.2M | -$219M | $314.4M | $407.2M | $77.4M | $81.5M | $118.63M | $99.22M | $89.77M | $53.06M | $43.37M | $32.07M | $31.94M | |
| $12.1M | $30.2M | $47.7M | $29.3M | -$7.4M | $83.5M | $102.1M | $22.9M | $18.8M | $36.04M | $36.7M | $26.9M | $16.32M | $13.11M | $13.92M | $15.83M | |
| -$8.6M | $52.6M | -$190.6M | -$760.5M | -$211.6M | $230.9M | $305.1M | $54.5M | $62.7M | $82.59M | $51.78M | $62.87M | $36.74M | $31.14M | $23.52M | $23.02M | |
| — | 7.08% | -18.26% | -72.48% | -18.94% | 12.88% | 19.62% | 4.93% | 8.01% | 14.73% | 10.59% | 12.03% | 8.16% | 9.96% | 8.35% | 8.42% | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$876K | -$5.38M | -$6.91M | |
| -$9.4M | $50.3M | -$190.1M | -$769.3M | -$192.4M | $240.1M | $289.7M | $50.1M | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.98 | -$3.60 | -$14.85 | -$4.22 | $4.32 | $5.79 | $1.06 | $1.25 | $1.98 | $1.29 | $1.63 | $0.98 | $0.86 | $0.65 | $0.65 |
| USD/shares | — | $0.93 | -$3.60 | -$14.85 | -$4.22 | $4.27 | $5.67 | $1.04 | $1.22 | $1.71 | $1.13 | $1.41 | $0.88 | $0.85 | $0.65 | $0.64 |
| shares | — | 53.5M | 53M | 51.2M | 50.1M | 53.5M | 52.7M | 51.5M | 50.1M | 41.82M | 40.18M | 38.6M | 37.34M | 36.2M | 36.08M | 35.66M |
| shares | — | 56.7M | 53M | 51.2M | 50.1M | 54.1M | 53.8M | 52.4M | 51.4M | 50.33M | 49.34M | 47.26M | 45.8M | 36.75M | 36.42M | 36.21M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $252.6M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.87×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| MCM Products Segment | $456,700,000 | $509,800,000 | $447,200,000 | $579,600,000 | $585,900,000 | — |
| Commercial Products Segment | $226,100,000 | $398,900,000 | $497,300,000 | $386,600,000 | $438,000,000 | — |
| Products Segment | — | — | — | $966,200,000 | $1,023,900,000 | $989,800,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $531,100,000 | $822,600,000 | $607,200,000 | $886,100,000 | $1,623,400,000 | $1,467,900,000 | $674,700,000 | $597,600,000 |
| Other Geographical Area | $136,800,000 | $80,600,000 | $217,900,000 | $82,800,000 | $83,500,000 | $63,400,000 | — | — |
| Canada | $75,000,000 | $140,400,000 | $224,200,000 | $148,600,000 | $66,700,000 | $46,000,000 | — | — |
| Non Us | — | — | — | — | — | — | $431,300,000 | $184,800,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Medical Countermeasures MCM Product | $456,700,000 | $509,800,000 | $447,200,000 | $579,600,000 | $585,900,000 | — | — | — |
| Commercial Product | $226,100,000 | $398,900,000 | $497,300,000 | $386,600,000 | $438,000,000 | — | — | — |
| All Other Revenue | $60,100,000 | $134,900,000 | $104,800,000 | — | — | — | — | — |
| Contract Development and Manufacturing | — | — | — | — | — | $450,500,000 | — | $98,900,000 |
| Contract Manufacturing | — | — | — | — | — | $450,500,000 | — | $98,900,000 |
| Contracts and Grants | — | $30,000,000 | $26,300,000 | $41,400,000 | $134,200,000 | $115,100,000 | $122,500,000 | $77,000,000 |
| Product and Service | — | $1,013,600,000 | $1,023,000,000 | — | — | — | — | — |
| Product | — | $908,700,000 | $944,500,000 | $966,200,000 | $1,023,900,000 | $989,800,000 | $903,500,000 | $606,500,000 |
| Service | — | $103,500,000 | $72,800,000 | $105,000,000 | $310,300,000 | $194,100,000 | $80,000,000 | — |
Key facts
CIK
1367644
CUSIP
29089Q105
13F (30d)
15 filings
15 filers
Visit website
Investor relations